NCT03899636View on ClinicalTrials.gov

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

528

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Stage III Pancreatic Cancer
Interventions
DRUG

Modified FOLFIRINOX Regimen

Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin

DEVICE

NanoKnife System

IRE using NanoKnife System

Trial Locations (6)

18045

St. Luke's Cancer Center, Easton

33176

Miami Cancer Institute, Miami

33606

University of South Florida/Tampa, Tampa

40202

Norton Healthcare, Louisville

60005

Northwest Community Healthcare, Arlington Heights

75231

University of Texas-Southwestern, Dallas

Sponsors
All Listed Sponsors
lead

Angiodynamics, Inc.

INDUSTRY